A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Trial Profile

A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Nov 2016 Results published in the Media Release
    • 01 Nov 2012 Planned End Date changed from 1 Sep 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top